Coherus Oncology Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
145
- Stock Symbol
-
CHRS
- Investments
-
3
- Share Price
-
$0.52
- (As of Friday Closing)
Coherus Oncology General Information
Description
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Contact Information
Website
www.coherus.comCorporate Office
- 333 Twin Dolphin Drive
- Suite 600
- Redwood City, CA 94065
- United States
Corporate Office
- 333 Twin Dolphin Drive
- Suite 600
- Redwood City, CA 94065
- United States
Coherus Oncology Timeline
Coherus Oncology Stock Performance
As of 13-Nov-2026, Coherus Oncology’s stock price is $0.52. Its current market cap is $81.2M with 155M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.52 | $0.54 | $0.50 - $2.62 | $81.2M | 155M | 1.69M | -$0.97 |
Coherus Oncology Financials Summary
As of 30-Sep-2026, Coherus Oncology has a trailing 12-month revenue of $53.6M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 121,293 | 20,668 | 331,180 | 718,445 |
| Revenue | 53,639 | 42,172 | 26,389 | 257,244 |
| EBITDA | (142,473) | (170,199) | (199,384) | (193,939) |
| Net Income | (135,935) | 168,024 | 28,507 | (237,892) |
| Total Assets | 171,104 | 258,343 | 448,533 | 629,604 |
| Total Debt | 54,497 | 40,336 | 269,904 | 480,842 |
Coherus Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Coherus Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Coherus Oncology Comparisons
Industry
Financing
Details
Coherus Oncology Competitors (80)
One of Coherus Oncology’s 80 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA | ||||
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Coherus Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Coherus Oncology Patents
Coherus Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226516-A1 | Methods of using anti-pd1 antibody | Pending | 21-Apr-2025 | ||
| WO-2026147940-A1 | Treatment of head and neck cancer | Pending | 03-Jan-2025 | ||
| AU-2023242749-A1 | Methods of treating cancer | Pending | 29-Mar-2022 | ||
| EP-4499116-A1 | Methods of treating cancer | Pending | 29-Mar-2022 | ||
| EP-4499116-A4 | Methods of treating cancer | Pending | 29-Mar-2022 | A61P35/00 |
Coherus Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Coherus Oncology Investments & Acquisitions (3)
Coherus Oncology’s most recent deal was a Merger/Acquisition with Surface Oncology for . The deal was made on 08-Sep-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Surface Oncology | 08-Sep-2023 | Merger/Acquisition | Drug Discovery | ||
| Innovent Biologics (Avastin Biosimilar in Canada) | 13-Jan-2020 | Corporate Asset Purchase | Buildings and Property | ||
| InteKrin | 12-Feb-2014 | Merger/Acquisition | Drug Discovery |
Coherus Oncology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.78 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Coherus Oncology Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Coherus Oncology (Legacy BioSimilar Assets) | Redwood City, CA |
Coherus Oncology FAQs
-
When was Coherus Oncology founded?
Coherus Oncology was founded in 2010.
-
Where is Coherus Oncology headquartered?
Coherus Oncology is headquartered in Redwood City, CA.
-
What is the size of Coherus Oncology?
Coherus Oncology has 145 total employees.
-
What industry is Coherus Oncology in?
Coherus Oncology’s primary industry is Drug Discovery.
-
Is Coherus Oncology a private or public company?
Coherus Oncology is a Public company.
-
What is Coherus Oncology’s stock symbol?
The ticker symbol for Coherus Oncology is CHRS.
-
What is the current stock price of Coherus Oncology?
As of 13-Nov-2026 the stock price of Coherus Oncology is $0.52.
-
What is the current market cap of Coherus Oncology?
The current market capitalization of Coherus Oncology is $81.2M.
-
What is Coherus Oncology’s current revenue?
The trailing twelve month revenue for Coherus Oncology is $53.6M.
-
Who are Coherus Oncology’s competitors?
Adaptimmune Therapeutics, Xenetic Biosciences, Vir Biotechnology, Dynavax Technologies, and CytomX Therapeutics are some of the 80 competitors of Coherus Oncology.
-
What is Coherus Oncology’s annual earnings per share (EPS)?
Coherus Oncology’s EPS for 12 months was -$0.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
